ArticleRMD open2018

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.

Edward C Keystone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.